Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Oral Janus associated kinase inhibitor '424 may prove superior to currently approved anti-TNF agents and Roche’s IL-6 inhibitor Actemra for RA, Incyte CEO says.